{"version":"1.0","provider_name":"Avalere Health Advisory","provider_url":"https:\/\/advisory.avalerehealth.com","title":"Manufacturer Considerations for Rare-Disease Drug Development | Avalere Health Advisory","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"f0yRI5RWRm\"><a href=\"https:\/\/advisory.avalerehealth.com\/insights\/manufacturer-considerations-for-rare-disease-drug-development\">Manufacturer Considerations for Rare-Disease Drug Development<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/advisory.avalerehealth.com\/insights\/manufacturer-considerations-for-rare-disease-drug-development\/embed#?secret=f0yRI5RWRm\" width=\"600\" height=\"338\" title=\"&#8220;Manufacturer Considerations for Rare-Disease Drug Development&#8221; &#8212; Avalere Health Advisory\" data-secret=\"f0yRI5RWRm\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","thumbnail_url":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2022\/01\/24922-1-Shelby_Harrington-400x600-1.jpg","thumbnail_width":600,"thumbnail_height":400,"description":"[vc_row][vc_column][vc_column_text]Drug manufacturers bringing therapies to market for rare diseases face challenges typically unseen with therapies for more prevalent conditions. These challenges span multiple stages\u2014from clinical development through commercialization\u2014and require coordinated efforts from medical affairs, health economics and outcomes research, policy, advocacy, and market access functions to execute successful evidence planning, stakeholder engagement, and patient access&hellip;"}